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S U M M A R Y
Fluoroquinolones (FQ) play an essential role in the treatment and control of multidrug-resistant
tuberculosis (MDR-TB). They are also being evaluated as part of newer regimens under development for
drug-sensitive TB. As newer FQ-based regimens are explored, knowledge of FQ resistance data from high
TB burden countries becomes essential. We examine available FQ resistance data from high TB burden
countries and demonstrate the need for comprehensive surveys to evaluate FQ resistance in these
countries. The factors driving FQ resistance in such conditions and the cost of such resistance to weak
healthcare systems are discussed. The need for a comprehensive policy for addressing the issue of FQ
resistance is highlighted.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The latest Global Tuberculosis Report estimates that 3.5% of
new and 20.5% of previously treated tuberculosis (TB) cases
diagnosed in 2013 were multidrug-resistant (MDR).1 There has
been considerable recent progress in the treatment of TB, and the
TB drug pipeline now holds the promise of a number of new TB
drugs, as well as novel regimens,2 including for the treatment of
MDR-TB. Despite such progress, the success rate for MDR-TB
treatment globally is reported to be only 48%, with weak
healthcare systems recognized as contributing to low cure rates.1
Weaknesses in healthcare systems are recognized to be drivers of
antimicrobial resistance in low- and low–middle-income countries
(LIC and LMIC).3
Fluoroquinolones (FQ) are broad-spectrum antibiotics that
were shown to be useful in the treatment of TB in 1984,4 and have
since become essential components of TB regimens, particularly
for drug-resistant disease (Table 1).
The emergence of FQ-resistant Mycobacterium tuberculosis
(MTB) is thus a cause for signiﬁcant concern. FQ act by inhibiting
DNA gyrase, an enzyme required for bacterial DNA synthesis. MTB
resistance to FQ is associated primarily with mutations in DNA
gyrase, a tetramer composed of two A and two B subunits, encoded
by gyrA and gyrB, respectively.13 Mutations in the gyrA gene are* Corresponding author. Tel.: +922134861640-41.
E-mail address: rumina.hasan@aku.edu (R. Hasan).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).associated with high-level FQ resistance, while mutations in gyrB
are associated with low-level resistance. A second mechanism
conferring FQ resistance in MTB is through efﬂux pumps that act by
removing the drug from bacterial cells.5,14
This review explores the relationship between FQ resistance in
TB and healthcare system constraints, and considers options for
addressing this concern.
2. FQ resistance in high TB burden countries
The 2014 Global Tuberculosis Report indicates a FQ resistance
rate of 17% in MDR-TB strains tested.1 Amongst the 22 high TB
burden countries, however, data on FQ-resistant MTB are limited,
with reports in some cases based on a small sample size (Table 2).
While much of the available FQ resistance data is for MDR-TB, FQ
resistance in non MDR-TB is reported from China, India, and
Pakistan (Table 2). The prevalence of FQ resistance in MTB has led
to discussions related to the use of FQ agents for infections other
than TB (in particular community-acquired pneumonia (CAP)) in
driving such resistance.40
3. Prior FQ exposure as a risk factor for FQ-resistant TB
FQ exposure is a recognized risk factor for the development of
FQ resistance in many nosocomial as well as community-acquired
pathogens.41–44 Higher FQ-resistant MTB in patients with a history
of respiratory infections has been attributed to widespread FQciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Fluoroquinolone agents used in the treatment of tuberculosis
Agent Activity against MTB
(MIC ranges, mg/ml)5
Use in TB treatment regimensa Programmatic recommendations (WHO)6,7
Second-generation
Oﬂoxacin 1.0–2.0 Has been used as ﬁrst- and second-line
agent8,9
Recommended for inclusion in MDR-TB
regimens
Not currently recommended as ﬁrst-line agent
Ciproﬂoxacin 0.5–4.0 In vitro activity, but may lack in vivo
efﬁcacy. Trials as ﬁrst-line agent for
drug-sensitive TB resulted in higher
relapse rates10,11
Not recommended
Levoﬂoxacin 1.0 More efﬁcacious than oﬂoxacin for
second-line treatment, but oﬂoxacin
resistance may lead to treatment
failure8,12
Recommended for inclusion in MDR-TB
regimens
Not currently recommended as ﬁrst-line agent
Third-generation
Gatiﬂoxacin 0.2–0.25 Has been used in standard ﬁrst- and
second-line regimens. New data on
shortened regimens available8
Not included in WHO guidelines. Lower
preference due to side effects
Fourth-generation
Moxiﬂoxacin 0.12–0.5 Has been used in standard ﬁrst- and
second-line regimens. New data on
shortened regimens available8
Recommended for inclusion in MDR-TB
regimens
Not currently recommended as ﬁrst-line agent
MTB, Mycobacterium tuberculosis; MIC, minimum inhibitory concentration; TB, tuberculosis; WHO, World Health Organization; MDR, multidrug-resistant.
a First- and second-line, where mentioned, refer to standard regimens. First-line treatment for drug-sensitive TB: 2 months of HRZE + 4 months of HR (where H = isoniazid,
R = rifampicin, Z = pyrazinamide, and E = ethambutol); 4 months of HRE is used in settings with high isoniazid resistance. Second-line treatment regimens are used for MDR-
TB; it is recommended that these include at least a ﬂuoroquinolone in addition to pyrazinamide, an injectable anti-TB drug, ethionamide (or prothionamide), and either
cycloserine or para-aminosalicylic acid.7
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of resistance in MTB has mostly been discussed in the context of
CAP.45–48 A recent meta-analysis evaluating the association of
prior FQ usage and the development of resistance in MTB reports a
three-fold higher risk of FQ-resistant MTB in patients prescribed FQ
before TB diagnosis.40 Prolonged FQ exposure (deﬁned as more
than 10 days of treatment), or multiple FQ prescriptions have been
highlighted as signiﬁcant risk factors for the development of FQ
resistance in MTB.45,49,50 Evidence such as this has led to strong
recommendations for avoiding FQ in national CAP guidelines.51
Despite these recommendations, the majority of national CAP
treatment guidelines in TB-endemic countries continue to include
FQ as ﬁrst-line treatment due to the fact that high global resistance
rates amongst respiratory pathogens to alternative agents,
including macrolides, limit options.48
A recent review of global FQ resistance rates reports a much
higher odds ratio for FQ resistance in MDR-TB as compared to non-
MDR-TB.52 Such resistance is associated with the use of a second-
line therapy including FQ in the management of MDR-TB31,52,53
and is attributed to inadequate treatment protocols.54,55 Hence
strict supervision of second-line therapy is recommended.56 These
recommendations are supported by a recent study from Taiwan,
where for both primary FQ resistance and acquired FQ resistance,
rates decreased signiﬁcantly following the implementation of a
successful directly observed therapy DOT-Plus programme.57
4. Impact of FQ resistance on MTB treatment
Considerable data are available reporting delayed sputum
culture conversion and treatment failure in TB patients with FQ
resistance.51,58–60 Resistance to oﬂoxacin has been linked with
delayed culture conversion in a recent study from Pakistan.61 An
earlier systematic review of 36 trials reporting end-of-treatment or
follow-up outcomes for MDR-TB patients had reported FQ
resistance as being associated with poor outcomes (including
any of death, default, transfer out, or treatment failure).62 While
the results of this review may have been biased due to trial and
outcome heterogeneity, the ﬁndings are nevertheless a cause forconcern given the signiﬁcant role of FQ in MDR-TB treatment.
These ﬁndings are consistent with another more recent study that
analysed individual patient data from 31 published cohorts of
patients with MDR-TB and extensively drug-resistant TB (XDR-
TB).63 Using data on drug sensitivity, treatment, and outcome
(cure/treatment completion, failure/relapse/death), this study
reports in vitro susceptibility to second-line drugs including FQ
as being consistently and signiﬁcantly associated with higher odds
of treatment success.63 More worrisome is the emergence of XDR-
TB strains in patients on second-line treatment. A study performed
in nine countries reported an XDR acquisition rate of 17% in
patients with baseline FQ resistance.53
Attempts to shorten the duration of ﬁrst-line TB therapy have
led to the inclusion of FQ in shorter, 4-month regimens.64 Recent
phase 3 trials of three such regimens, two containing moxiﬂoxacin
and the third gatiﬂoxacin, do not show non-inferiority of the
shorter regimens, indicating that shortening treatment to 4 months
was not effective.65–67 Moreover, these regimens have raised
concern about the efﬁcacy in areas with high FQ resistance,
wherein treatment failure and the emergence of MDR-TB strains is
likely.
In contrast, excellent outcomes for a 9-month gatiﬂoxacin-
based regimen have increased optimism for improved and shorter
MDR-TB management.68–71 However, given that FQ resistance was
the strongest risk factor for a bacteriologically unfavourable
outcome, the protocol needs to be evaluated in high FQ-resistant
TB settings.71 Whether a higher dose of newer FQ may still be
successful in such settings requires investigation.
5. Cross-resistance to newer FQ and other second-line TB drugs
The use of newer FQ for the management of oﬂoxacin-resistant
MDR- and XDR-TB is recommended.72 Nevertheless, a signiﬁcant
proportion of oﬂoxacin-resistant strains are also resistant to the
newer FQ.36,73,74 Newer FQ should thus not be used indiscrimi-
nately for drug-resistant TB in high FQ resistance settings without
prior susceptibility testing.59,75 Additionally FQ resistance has
Table 2
Fluoroquinolone resistance in Mycobacterium tuberculosis in high TB burden countries (2004–2014)
Country Location Study period Population (n) Resistance as % of strains tested (number resistanta)b
CIP OFX LVX MXF GAT FQb
Bangladesh Dhaka15 2013 PT cases (84) 8.3 5.9
Brazil Rio16 2001 MDR (8) 0 0 0 0
China Deqing County17 2004–2005 Non-MDR (146) 5.5 1.4 2
MDR (18) 17 11 5.6
Guanyun County17 2004–2005 Non-MDR (152) 7.2 3.2 3.2
MDR (35) 5.7 5.7 2.9
National DR-TB survey18 2007 All cases N (3037) 2.7
PT (829) 8.7
MDR N (175) 24.9
PT (226) 27.5
Shandong Province19 2007–2009 MDR N (47) 66
PT (18) 83
Lianyungang City20 2011–2012 Smear-positive N (816) 5.1
PT (196) 18.4
Ethiopia Amhara Region21 2009 Smear-positive N (241) 0
PT (46) 0
India Nationwide22 2001–2004 MDR PT (1498) 11.3
Delhi23 2008–2009 Non-MDR (47) 14.9
MDR (55) 38.2
Delhi24 2007–2010 Non-MDR (231) 20.7
MDR (130) 36.2
Tibetan refugee
settlements25
2010–2011 MDR N (28) 28.6
PT(23) 21.7
Indonesia Mimika District26 2003–2004 MDR (12) 0
Pakistan Karachi27 1996–2006 MDR (577) 7
Nationwide
laboratory-based28
2005–2006 MDR (1371) 17.5
2007 MDR (782) 20.8
2008 MDR (991) 35.4
2009 Non-MDR (1560) 3
MDR (1181) 43
Karachi,
community-based29
2006–2009 Non-MDR N (131) 4.6
PT (21) 4.8
MDR N (21) 4.8
PT (24) 16
Philippines Manila30,31 2003–2008 MDR (2485) 7
2005–2008 MDR (397) 7.1
Russian Federation Vladimir32 2006 MDR N (22) 0
PT (160) 18
Orel32 2006 MDR N (18) 1
PT (57) 23
Archangel33 2005 MDR (77) 2.3
Orel, Vladimir31 2005–2008 MDR (115) 18.3
S. Africa 4 provinces31 2005–2008 MDR (293) 12.6
Cape Town34 2007–2009 MDR Children (26) 7.7
Cape Town35 2009–2011 MDR Children (23) 22
Thailand Nationwide36 2003–2011 MDR N 10.2 (38) 5 (17) 3.8 (13) 0.9 (3)
PT 15.4 (62) 8.3 (29) 6.4 (23) 2 (7)
Total 15 (191) 8.6 (97) 6.7 (77) 2.2 (25)
4 provinces31 2005–2008 MDR (51) 9.8
Nationwide37 2001–2009 MDR 10.3 (70) 7.2 (34) 4.9 (24) 1.3 (6)
Uganda Kampala38 2003–2006 MDR (51) 5.9
UR Tanzania39 2009–2010 All cases N (291) 0.7 0.35
TB, tuberculosis; CIP, ciproﬂoxacin; OFX, oﬂoxacin; LVX, levoﬂoxacin; MXF, moxiﬂoxacin; GAT, gatiﬂoxacin; FQ, ﬂuoroquinolone (ciproﬂoxacin/levoﬂoxacin/oﬂoxacin); PT,
previously treated patients; MDR, multidrug-resistant; DR, drug-resistant; N, new patients. Published data from the following high-burden countries could not be identiﬁed
and thus were not included: Afghanistan, Cambodia, DR Congo, Kenya, Mozambique, Myanmar, Nigeria, Vietnam, and Zimbabwe.
a Number resistant is shown where the study sample was not uniform for each FQ tested.
b FQ resistance among non-MDR-TB is shown in bold font.
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line and second-line agents used in the treatment of TB.76
6. Healthcare system constraints driving FQ resistance
While a number of factors may contribute to FQ resistance in
the community, resistance in MTB is driven to a signiﬁcant extent
by poor FQ pharmacokinetic/pharmacodynamic (PK/PD) exposure
in patients with active disease.77 Such faulty dosing stems as much
from insufﬁcient implementation of regulations related to the use
of FQ in TB or CAP, as from inadequate regulations for controlling
drug quality and antimicrobial usage in the community.Inappropriate TB treatment by inadequately trained profes-
sionals, physicians, pharmacists, and allied health workers,
particularly in the private sector, is common in weak healthcare
systems.78 Many TB patients receive either unwarranted FQ
therapy or treatment with alternative FQ with poor activity. In
high TB burden countries, up to 30% of patients receive
ciproﬂoxacin,79 an agent not recommended for use in TB due to
narrow mutant prevention windows.50
Both counterfeit as well as substandard FQ preparations are rife
in many developing countries.80 The use of counterfeit antibiotics
has been reported from Nigeria, India, Bangladesh, Burma,
Cameroon, Vietnam, Cote d’Ivoire, and several other countries.81
• Impl ementation of FQ DST prior to initia ting F Q-based first-  or second-line TB 
drug regimens 
• Increase surveillance for FQ-resi stant MTB in high TB burden settings including 
amongst non-MDR-TB strains 
• Increase training of physicians particularly in the private sector to correctly 
diagnose and treat active TB disease 
• In  high  burden  settings, ensure responsible use of FQ in non-TB infections 
particularly CAP 
• Closer integration of TB program mes within  the  healt hcare  syste m to  allow 
screening of patients with repeated and chronic  respiratory  infections  for  MTB 
• Healthcare  syste m stren gthening  to  improve  diagnostics  including  DST  overall, 
including for bacteria other than MTB, and thus imple mentation of directed and 
appropriate care 
• Policies to apprehend OTC FQ sales 
• A co mprehensive appr oach to re gistering phar maceuticals,  monitoring of 
manufacturing quality and distribution practices, and post- marketing audits of 
available formulations 
• Monitoring of FQ consumption in the country  including  for  veterinary  usage 
• Impl ementation of the One Health  Concept   
Figure 1. Suggestions for containment of ﬂuoroquinolone resistance in
Mycobacterium tuberculosis (FQ, ﬂuoroquinolone; DST, drug-sensitivity testing;
TB, tuberculosis; MTB, Mycobacterium tuberculosis; MDR, multidrug-resistant; CAP,
community-acquired pneumonia; OTC, over-the-counter).
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preparations include inadequate approval and regulatory policies
and improper manufacturing practices and quality assurance in
manufacturing.82 In India alone, >60 000 brands of various drugs
are marketed, but are not registered,83 therefore not subject to any
policies that may exist.
In such systems, antibiotics are often used as a substitute for
poor policy control and regulations and to ﬁll practice gaps in
preventing infections, e.g., vaccine coverage, hygiene practices, and
health education of communities.84 Such usage is promoted by
physician behaviour and malpractice. Prescriptions for monetary
beneﬁts or for incentives offered by manufacturers or vendors of
counterfeit FQ preparations abound in high TB burden countries.83
Hospitals may also rely on pharmaceuticals for the generation of
income for employees.78 Prescription malpractice also includes
offering more expensive brands to well-off patients and cheaper
brands to the poor or uninsured, resulting in sustained sales of
counterfeit drugs of varying quality.78
The over-the-counter (OTC) sale of drugs is in fact an important
predictor of FQ-resistant MTB.85 TB patients, mostly belonging to
the lower socioeconomic strata of society and unable to afford
costly private physician consultations,86 self-medicate with
better-known (and pharmacy-driven) antibiotics including those
for CAP.87
In the generation of FQ-resistant MTB, the contribution of FQ in
the non-healthcare-associated environment is also signiﬁcant. This
includes the presence of small amounts of FQ in the food chain as a
result of unregulated use in farm animals, as growth supplements
in medicated feeds,88 in aquaculture,89 in domestic water
contaminated with farm efﬂuents,90 and in adulterated food
products.91Moreover in high TB burden countries where farming is
often the principal occupation, a number of patients have direct
contact with sick animals on therapeutic veterinary FQ. Despite the
US Food and Drug Administration ban on the veterinary use of
enroﬂoxacin,92 it is still used in countries with weak healthcare
systems.93 Oxolinic acid and ﬂumequine are other quinolones in
common use by farms, veterinarians, and in aquaculture that have
documented cross-resistance with FQ for human use.92
An equally important contributor to the increased consumption
of FQ (hence resistance) in weak healthcare systems is the lack of
availability of reliable antibiotic susceptibility data,84 both for MTB
and for other bacterial infections. Inadequate surveillance strate-
gies, poor quality laboratory data, and limited awareness of
resistance epidemiology among healthcare workers lead to the
overuse of FQ in CAP, assuming beta-lactam or tetracycline
resistance. The generation of such data is essential for creating
awareness and better therapeutic regimens.
7. The cost of increasing FQ resistance in weak healthcare
systems
We have described the many inadequacies of weak healthcare
systems leading to FQ resistance in TB. Here, we outline the
burgeoning inadequacies in weak healthcare systems that in turn
result from FQ resistance in MTB. The operational goals of
healthcare systems are health, responsiveness, and ﬁnancial risk
protection for the community.94 Increasing FQ resistance in MTB
affects each of these goals directly or indirectly.
7.1. Financial impact
The treatment of several diseases requires out-of-pocket
expenditure for patients and TB is no different. Despite the efforts
of the World Health Organization and the Stop TB Partnership
toward DOTS and DOTS-Plus coverage in high TB burden countries,
weak healthcare systems are unable to ensure 100% treatmentcoverage; the contribution of the private sector in such care is thus
considerable. As highlighted above, FQ resistance may result in
either poly or XDR-TB. The cost of XDR-TB treatment, prolonged
regimens, unaffordable medications, and surgery are still borne by
patients to a considerable extent. Adding to this cost are the
emotional and social costs of depression due to prolonged illness,
poverty, and social isolation.
7.2. Impact on health
Any antibiotic resistance directly affects population health
through adding to the microbial resistance gene pool and making
eradication/control difﬁcult. Health equity is also affected by a
mismatch of resources against the greatest need. FQ are
increasingly prescribed for other infections for which other
effective treatments exist,95 in contrast to TB, for which a limited
number of anti-TB drugs are known.
7.3. Impact on responsiveness
Public health responsiveness to manage community expecta-
tions is affected directly as a consequence of resistance.
Communities now know TB to be a treatable disease, however
expectations are not met when XDR-TB or MDR-TB with FQ-only
resistance (pre-XDR) fail treatment. Moreover, there are increas-
ingly fewer resources to meet other expectations such as contact
tracing and prevention in such cases.
All such constraints on the healthcare system lead to sustained
transmission and an increasing incidence of FQ-resistant TB.
K. Jabeen et al. / International Journal of Infectious Diseases 32 (2015) 118–1231228. Approach to the problem of FQ-resistant MTB
Keeping in view the manifold and system-wide causes of the
increase in FQ resistance, the response to contain resistance must
also be system-wide. The development and approval of policies to
overcome the aforementioned constraints are the ﬁrst steps
required. These are summarized in Figure 1.
Addressing workforce shortages and training inadequacies are
the next steps in strengthening systems. Initiatives must involve
all components of the healthcare system, agriculture, aquaculture,
and animal health following the model of the One Health Initiative,
which proposes that the integration of human with veterinary and
environmental health interventions enhances disease control
efforts.96
However, in weak healthcare systems, the challenge is the
implementation of policies. To facilitate implementation, policy-
makers must also ensure cultural acceptability, economic feasibil-
ity, and endorsement by the healthcare community. The allocation
of resources, redistribution of ﬁnances, and recruitment of public,
private, and international funders, as well as stakeholder engage-
ment, are essential to improve policy responsiveness. If these steps
can be taken by policymakers at a national level, healthcare
systems can be improved to incorporate stewardship of FQ usage.
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